Dr. Devika G. Das

Claim this profile

Veterans Administration Medical Center - Birmingham

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
13 drugs studied

Area of expertise

1Lung Cancer
Devika G. Das has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
EGFR negative
ALK negative
2Non-Small Cell Lung Cancer
Devika G. Das has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
MET positive
PD-L1 positive

Affiliated Hospitals

Image of trial facility.
Veterans Administration Medical Center - Birmingham
Image of trial facility.
University Of Florida Health Science Center - Gainesville

Clinical Trials Devika G. Das is currently running

Image of trial facility.

Iadademstat + Atezolizumab/Durvalumab

for Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.
Recruiting1 award Phase 1 & 25 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria

More about Devika G. Das

Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Devika G. Das has experience with
  • Cabozantinib S-malate
  • Nab-paclitaxel
  • Nivolumab
  • Biospecimen Collection
  • Data Collection
  • Quality-of-Life Assessment

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Devika G. Das specialize in?
Is Devika G. Das currently recruiting for clinical trials?
Are there any treatments that Devika G. Das has studied deeply?
What is the best way to schedule an appointment with Devika G. Das?
What is the office address of Devika G. Das?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security